Dysferlin overexpression in skeletal muscle produces a progressive myopathy

Annals of Neurology

Volumn 67, Issue 3, 2010, Pages 384-393

  Glover, Louise E ^a,b   Newton, Kimberly ^a   Krishnan, Gomathi ^c   Bronson, Roderick ^d   Boyle, Alexandra ^a   Krivickas, Lisa S ^c   Brown Jr , Robert H ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; CHAPERONE; DYSFERLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOPLASMIC RETICULUM STRESS; GENE OVEREXPRESSION; GRIP STRENGTH; HISTOLOGY; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE DISEASE; MUSCLE STRENGTH; MYOBLAST; MYOPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SARCOLEMMA; SKELETAL MUSCLE; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KYPHOSIS; LAMENESS, ANIMAL; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MUSCLE PROTEINS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; PHENOTYPE; PROMOTER REGIONS, GENETIC; STRESS, PHYSIOLOGICAL;

EID: 77950540738     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21926     Document Type: Article

References (44)

1. Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998;20: 37-42. (Pubitemid 28410340)
2. Liu J, Aoki M, Illa I, Wu C, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20:31-36. (Pubitemid 28410339)
3. Saito A, Higuchi I, Nakagawa M, et al. Miyoshi myopathy patients with novel 5′ splicing donor site mutations showed different dysferlin immunostaining at the sarcolemma. Acta Neuropathol 2002;104:615-620. (Pubitemid 36075427)
4. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003;423: 168-172. (Pubitemid 36569539)
5. Lennon NJ, Kho A, Bacskai BJ, et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 2003;278:50466- 50473. (Pubitemid 37548892)
6. Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 2001;106:157-169.
7. McNeil PL, Terasaki M. Coping with the inevitable: how cells repair a torn surface membrane. Nat Cell Biol 2001;3: E124-E129. (Pubitemid 32422077)
8. Ho M, Post CM, Donahue LR, et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004;13:1999-2010. (Pubitemid 39377824)
9. Piccolo F, Moore SA, Ford GC, Campbell KP. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. Ann Neurol 2000;48:902-912.
10. Selcen D, Stilling G, Engel AG. The earliest pathologic alterations in dysferlinopathy. Neurology 2001;56:1472-1481.
11. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004;10:828-834. (Pubitemid 39070856)
12. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005;23:321-328. (Pubitemid 41094420)
13. Cerletti M, Negri T, Cozzi F, et al. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirusmediated utrophin gene transfer. Gene Ther 2003;10:750-757. (Pubitemid 36621818)
14. Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12:787-789. (Pubitemid 44050067)
15. Rodino-Klapac LR, Shontz KM, Malik V, et al. rAAV5 mediated delivery of dysferlin as a therapeutic strategy for LGMD2B and Miyoshi myopathy. Paper presented at: Twelfth Annual Meeting of the American Society of Gene Therapy; May 27-30, 2009; San Diego, CA.
16. Ghosh A, Yue Y, Long C, Bostick B, Duan D. Efficient wholebody transduction with trans-splicing adeno-associated viral vectors. Mol Ther 2007;15:750-755. (Pubitemid 46431995)
17. Muscat GE, Kedes L. Multiple 5-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression. Mol Cell Biol 1987;7:4089-4099.
18. Brennan KJ, Hardeman EC. Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. J Biol Chem 1993; 268:719-725. (Pubitemid 23021382)
19. Anderson LV, Davison K, Moss JA, et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999;8:855-861. (Pubitemid 29189053)
20. Sharp AH, Imagawa T, Leung AT, Campbell KP. Identification and characterization of the dihydropyridine-binding subunit of the skeletal muscle dihydropyridine receptor. J Biol Chem 1987; 262:12309-12315.
21. Ho M, Gallardo E, McKenna-Yasek D, et al. A novel, bloodbased diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002;51:129-133. (Pubitemid 34027987)
22. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem 1995;118:959-964.
23. Bischoff R, Heintz C. Enhancement of skeletal muscle regeneration. Dev Dyn 1994;201:41-54.
24. Doherty KR, Cave A, Davis DB, et al. Normal myoblast fusion requires myoferlin. Development 2005;132:5565-5575. (Pubitemid 43125882)
25. Larsson L, Moss RL. Maximum velocity of shortening in relation to myosin isoform composition in single fibres from human skeletal muscles. J Physiol 1993;472:595-614. (Pubitemid 24015023)
26. Krivickas LS, Fielding RA, Murray A, et al. Sex differences in single muscle fiber power in older adults. Med Sci Sports Exerc 2006;38:57-63. (Pubitemid 43062957)
27. Edman KA. The velocity of unloaded shortening and its relation to sarcomere length and isometric force in vertebrate muscle fibres. J Physiol 1979;291:143-159.
28. de Luna N, Gallardo E, Soriano M, et al. Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro." J Biol Chem 2006;281:17092-17098.
29. De Luna N, Gallardo E, Illa I. In vivo and in vitro dysferlin expression in human muscle satellite cells. J Neuropathol Exp Neurol 2004;63:1104-1113.
30. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002;110:1389-1398. (Pubitemid 35396907)
31. Ikezoe K, Furuya H, Ohyagi Y, et al. Dysferlin expression in tubular aggregates: their possible relationship to endoplasmic reticulum stress. Acta Neuropathol 2003;105:603-609. (Pubitemid 36798861)
32. Millay DP, Maillet M, Roche JA, et al. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 2009;175:1817-1823.
33. Dressman D, Araishi K, Imamura M, et al. Delivery of alpha-and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther 2002; 13:1631-1646.
34. Zhu X, Hadhazy M, Groh ME, et al. Overexpression of gammasarcoglycan induces severe muscular dystrophy. Implications for the regulation of sarcoglycan assembly. J Biol Chem 2001;276: 21785-21790. (Pubitemid 37413181)
35. Cox GA, Cole NM, Matsumura K, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993;364:725-729.
36. Huang Y, Verheesen P, Roussis A, et al. Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur J Hum Genet 2005;13:721-730. (Pubitemid 40846844)
37. Anderson LV, Harrison RM, Pogue R, et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dys- trophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000;10:553-559.
38. Chrobakova T, Hermanova M, Kroupova I, et al. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. Neuromuscul Disord 2004;14: 659-665. (Pubitemid 39194666)
39. Spencer MJ, Guyon JR, Sorimachi H, et al. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proc Natl Acad Sci U S A 2002;99:8874-8879. (Pubitemid 34693651)
40. Saito Y, Ihara Y, Leach MR, Cohen-Doyle MF, Williams DB. Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins. EMBO J 1999;18: 6718-6729.
41. Groenendyk J, Lynch J, Michalak M. Calreticulin, Ca2+, and calcineurin-signaling from the endoplasmic reticulum. Mol Cells 2004;17:383-389.
42. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev 2008;8: 663-674.
43. Fujita E, Kouroku Y, Isoai A, et al. Two endoplasmic reticulumassociated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet 2007;16: 618-629.
44. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824-1835. (Pubitemid 40852891)